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AN OVERVIEW OF IRON METABOLISM
Iron is a prerequisite for in vitro growth of mycobacteria.
Iron is an obligate cofactor for at least 40 different enzymes
encoded in the Mycobacterium tuberculosis genome (8). It is
required for the cytochromes involved in electron transport
and other hemoproteins involved in oxygen metabolism, such
as catalase-peroxidase KatG. Most of the intracellular iron in
mycobacteria, however, is in the form of nonheme iron (48).
One important form of nonheme iron is the iron-sulfur clusters
that are cofactors of proteins involved in amino acid and
pyrimidine biogenesis, as well as in enzymes involved in the
tricarboxylic acid cycle and electron transport. Iron is also
required for DNA synthesis in ribonucleotide reductase,
superoxide dismutase, and 3-deoxy-D-arabino-heptulosonate
7-phosphate synthase (Rv2178c; DAHP synthase [Every gene
in the genome of M. tuberculosis H37Rv has been assigned a
gene identifier beginning with Rv which can be used to retrieve
information on line; see reference 30a]). It has been estimated
that 7 to 64 mg of Fe/g of mycobacterial cell mass is required to
support growth (39, 48). Iron limitation in vitro to levels below
these can result in growth restriction in many species of my-
cobacteria, including pathogens such as M. tuberculosis. Since
iron is the fourth most abundant element, difficulty in its ac-
quisition may seem counterintuitive. However, the extremely
low solubility of ferric ion in aqueous solution makes obtaining
it difficult and so microorganisms have evolved many strategies
for acquiring sufficient soluble iron for aerobic growth.
Iron sequestration represents a formidable challenge to in
vivo growth of pathogenic mycobacteria. An important com-
ponent of the mammalian host defense against bacterial patho-
gens involves restricting access of such organisms to iron (35).
M. tuberculosis is a highly specialized pathogen of humans and
must contend with iron sequestration in order to survive in the
human lung. Pulmonary tuberculosis patients are often ane-
mic, suggesting sequestration of available iron by the host (5).
The serum of many mammals, including humans, is tubercu-
lostatic because of its ability to sequester iron from the bacilli
(32, 34). The addition of iron to such sera relieves the bacte-
riostatic effect completely. In a tragic attempt to rectify what
was perceived as a debilitating iron deficiency in infected pa-
tients in Somalia, iron supplementation was found to actually
promote the development of active tuberculosis (54). Other
clinical studies in Africa have also established a strong corre-
lation between dietary iron overload and an enhanced risk of
death from tuberculosis (20, 52). Purified transferrin inhibits
the growth of M. tuberculosis in vitro (33), and haptoglobin may
play a role in restricting access to heme iron (29, 57). Thus,
iron availability or sequestration and the bacterium’s efforts to
circumvent this restriction are critical determinants of the out-
come of infection with M. tuberculosis.
Infections with mycobacteria of the M. avium complex
(MAC) occur predominantly in human immunodeficiency vi-
rus-infected patients and are a major source of mortality for
such patients. Iron storage in macrophages is known to be
increased in patients with AIDS (although overall iron levels in
serum are lower than those of patients without AIDS), and this
observation has been proposed to underlie the predisposition
of such patients to MAC infections (11, 12, 22). Animal model
experiments support this hypothesis in that mice fed iron-rich
diets more rapidly develop disease from MAC (11). In cultured
human macrophages, the rate of MAC replication has been
shown to be directly correlated with the concentration and iron
loading of transferrin (12).
Mycobacterial iron acquisition is mediated by siderophores.
The problem of iron acquisition has been solved by many
microorganisms, including mycobacteria, by producing small,
soluble iron chelators known as siderophores. These sub-
stances are generally secreted by the organism to compete with
environmental iron binding molecules for the small amount of
available iron. Siderophore synthesis is typically controlled by
extracellular iron abundance, and these molecules display a
high affinity for ferric iron. Four types of structurally distinct
molecules are thought to be involved in iron acquisition in
mycobacteria, salicylic acid and citric acid being the simplest,
followed by two classes of more complex siderophores. The
first, the mycobactins (MBs), are distinguished primarily by the
presence of a phenyloxazolidine ring, while the second class,
the exochelins, are peptidic siderophores whose iron-chelating
ability is associated with ornithine-derived hydroxamates. MBs
and exochelins are complex molecules with very high affinities
for iron and are integral to the bacterial strategy for obtaining
iron from the environment.
Early work focused on the dramatic accumulation of salicylic
acid secreted into the growth medium coincident with iron
starvation of either slow-growing or fast-growing mycobacte-
rial species (60). Salicylate was postulated to be an important
extracellular siderophore, but the stability of the salicylate-iron
complex appears to be too low to support this hypothesis.
However, the amount of salicylate secreted into growth media
upon iron starvation reaches as much as 2.28 mg/100 ml of
medium and this concentration suggests a secondary physio-
logical role, perhaps in facilitating iron solubilization (60).
Citric acid has also been proposed to be involved in iron
acquisition in M. smegmatis on the basis of cell association of
an iron-citrate complex (51). However, the very high concen-
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trations of citric acid required, the lack of inducibility of citrate
synthesis upon iron starvation, and the lack of an energy-
dependent specific uptake system for such complexes all argue
against such a role.
The MBs and exochelins (Fig. 1A and B) are produced
specifically in response to iron starvation and are known to
have a high affinity for iron(III). The increase in MB produc-
tion in iron-limiting medium has been recognized since the
very first isolation work (15). Iron sufficiency has been reported
to decrease MB content by as much as 10,000 times (45, 59),
although a much smaller decrease is generally reported (58).
Mycobacterial species fall into four groups based upon the
expression of these molecules. M. tuberculosis produces only
the MB type of siderophore, M. vaccae produces only the
exochelin type, M. smegmatis produces both types, and some
strains of M. paratuberculosis produce none (50, 60). The real
distribution of organisms among these groups is difficult to
assess precisely because of substantial confusion over the use
of the term exochelin (when what is meant is a water-soluble
MB or a mixture of MBs and exochelins in species which
produce both). Many authors equate exochelin with water-
soluble MB in spite of the fact that exochelin was first pro-
posed to represent the non-salicylate-containing peptidic sid-
erophores of M. smegmatis (Fig. 1B) (70, 71). Use of the term
exochelin should be limited to those molecules structurally
related to the peptidohydroxamate siderophores typified by the
structure of exochelin MS (Fig. 1B). Molecules related to the
salicylate-containing siderophores which contain chemical
functionality rendering them more water soluble should be
more properly referred to as MBs (or water-soluble MBs, also
referred to as exomycobactins [84]). Some strains of mycobac-
teria, in particular, of M. paratuberculosis, that do not produce
any siderophores are dependent for growth upon the inclusion
of such molecules in the medium (4, 24, 79). Species, such as
M. bovis, which produce only MBs are not able to utilize
water-soluble peptidic exochelins for uptake of iron (77). In
vitro growth of an MB-deficient mutant of M. tuberculosis
H37Rv was significantly impaired under low-iron conditions
compared to the wild-type strain, supporting a critical role for
this molecule in iron acquisition and transport (10).
The interplay of cell-associated and secreted siderophores
in iron acquisition. In many species of mycobacteria, it has
been noted that two forms of siderophore are often present,
one primarily cell associated and one secreted or medium
associated. This has given rise to a hypothesis that there are
two distinct roles for such molecules. The extracellular form
competes directly for environmental iron, while the cell-asso-
ciated form acts as an ionophore, facilitating transport into the
cell cytoplasm (43, 64). The water-soluble form of MB from M.
bovis BCG (confusingly labeled exochelin MB-2) is capable of
supporting ferritin-dependent growth of M. bovis BCG even
when the iron source is separated from the growing cells by a
dialysis membrane (43). The restriction of growth which ac-
companies culture of the tubercle bacillus in serum can be
reversed by addition of MB and transferrin or ferritin but not
by that of either molecule alone (19). More recently, the water-
soluble MBs of M. tuberculosis (again confusingly mislabeled
exochelins) were shown to acquire iron from 40% iron-satu-
rated transferrin and to transfer this iron to the cell-associated
MBs (17). Transferrin receptors, and presumably therefore
transferrin, are present in the phagosomal membrane sur-
rounding living M. tuberculosis within human monocytes (7).
These experiments support the hypothesis that both soluble
and cell-associated forms of siderophore are required for iron
acquisition from the mammalian host in vivo for mycobacterial
pathogenesis. Finally, and definitively, the availability of a
knockout in the biosynthetic pathway which produces both
forms of MB in M. tuberculosis has allowed us to demonstrate
that a mutant incapable of producing both types of MBs has
lost the ability to grow within macrophages (10). The definitive
experiments regarding the hypothetical specific role for cell-
associated compared to secreted siderophores must await the
identification and specific modification of the acyl transferases
which attach the R5 chain. These bifurcate the biosynthetic
pathway and determine the ultimate ratio of MB to water-
soluble MB produced by M. tuberculosis.
Storage of iron in mycobacterial species. Mycobacterial sid-
erophores are thought to be taken up and transported across
the cell membrane by specific receptors and transporters, by
analogy to other siderophore uptake mechanisms. Siderophores
are transient reservoirs of iron which bind to ferric iron during
transport into the cell cytoplasm. Recent experimental evi-
dence shows that very little intracellular iron is contained
within these molecules on a long-term basis (31). In situ Mo¨ss-
bauer spectroscopy and electron paramagnetic resonance spec-
troscopy have been used to confirm these results, as signals
associated with siderophore-bound iron are only observed
upon short-term labeling of iron pools with 57Fe (46, 47).
Long-term labeling experiments have revealed that under iron-
sufficient conditions, iron is accumulated in a form with spec-
tral parameters consistent with bacterioferritin (46). Bacterio-
ferritin proteins have been purified from M. leprae (55), and a
bacterioferritin gene has been cloned from M. avium (30). On
the chromosome of M. tuberculosis, there are apparently two
bacterioferritin homologs, bfrA (Rv1876) and bfrB (Rv3841)
(2).
STRUCTURE OF MYCOBACTERIAL SIDEROPHORES
An invariant “core” MB structure. The structure of MB P,
isolated from M. phlei, was initially established through chem-
ical degradation by Snow (74). Since that time, a large number
FIG. 1. Siderophores of mycobacterial species. (A) Structure of the major
MB of M. tuberculosis (MB T). (B) Structure of the major exochelin of M.
smegmatis (exochelin MS). Peptidic siderophores such as exochelin MS have only
been identified from fast-growing saprophytic strains, while MBs such as that
shown in panel A have been found widely distributed among mycobacterial
species.
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of MBs have been isolated but their core structure displays
remarkably little variation (Fig. 2) (73). They all have a 2-hy-
droxyphenyloxazoline moiety linked via an amide bond to an
acylated e -N-hydroxylysine residue. This lysine is, in turn, es-
terified at the a-carboxyl with a b-hydroxy acid that forms an
amide link with a second e -N-hydroxylysine which has cyclized
to give a seven-membered lactam. The absolute configurations
of the stereogenic centers derived from an amino acid (where
known) all appear to arise from the naturally occurring L
series. This basic structure serves to chelate ferric iron very
effectively via the two hydroxamic acids of the e -N-hydroxyly-
sines, the N of the oxazoline ring, and the phenolate oxygen
atom (25). Although a formation constant of 1030 M21 is
widely quoted, the only direct measurements have monitored
the dissociation of 59Fe-labeled ferri-MB S under strongly
acidic conditions. From this data, one can extrapolate a for-
mation constant of approximately 4 3 1026 M21 at pH 7 (41).
Coordination to ferrous iron by MB is much less effective,
allowing release of iron from a ferri-MB complex by reduction.
Computational work suggests that the reason for ferric ion
selectivity lies in the confluence of the size of the ferric cation
and the cavity created by a sterically favorable organization of
the ligand (40).
Within this core of the MB, a methyl group may or may not
be present at the position 6 of the phenolic ring (R1) and/or at
the 59 position of the oxazoline (R2) (Fig. 3). The presence of
both types of oxazoline in M. tuberculosis has been reported
(18), and MBs containing both aromatic moieties are found in
M. fortuitum (75). One final core variation seen in some of the
MBs from Nocardia sp. (the nocobactins) is an aromatic ox-
azole in place of the oxazoline ring (53, 65).
Variation in alkyl substitution patterns of MBs. In contrast
to the relatively subtle variation seen in the nuclei of MBs, the
alkyl substituents of the hydroxy acid (R3 and R4) and the acyl
moiety R5 are highly variable (Fig. 3) (73). The b-hydroxy acid
is usually b-hydroxybutyrate or 2-methyl-3-hydroxypentanoic
acid. Both absolute configurations of the b-hydroxybutyrate
have been reported from different MBs (75). Similarly, the
absolute stereochemistry of the 2-methyl-3-hydroxypentanoic
acid has been reported, and although the relative stereochem-
FIG. 2. General structure of MBs. Iron-chelating groups are in boldface.
Letters and R groups correspond to the structures listed in Fig. 3.
FIG. 3. General structures of known MBs. Symbols: p, the terminal carbon in this chain of this water-soluble MB is either a carboxylic acid or its methyl ester; †,
the structure as originally reported (49); §, MB that contains an oxazole moiety instead of the usual oxazoline and is found in Nocardia sp; ‡, letters refer to the
stereocenters shown in the structure above, 2 indicates that the center is not chiral in this compound, and ? indicates that the stereochemistry is unknown.
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istry is always erythro, both absolute configurations are seen in
different MBs. There are also reports of more complex b-hy-
droxy acids with branched chains (R3 5 i-Pr, R4 5 Me) (49),
long-chain alkyl substituents (R3 5 C15–18, R4 5 Me) (3, 75),
or both (R3 5 C9, R4 5 Me2) (53) being employed.
The acyl moiety (R5) is the source of most of the observed
structural variation in the MBs (73). In general, the acyl group
is a long-chain fatty acid (C10 to C21) that is often unsaturated
with an unusual cis double bond conjugated to the carbonyl
group (73). However, enormous variation on this theme is
observed. Ratledge and Ewing detailed 17 different MBs from
a single strain of M. smegmatis that differ only at R5; 7 of these
compounds were present in significant amounts (61)! Thin-
layer chromatography and high-performance liquid chroma-
tography have been employed extensively, with some success,
to identify strains of mycobacteria to the species level; how-
ever, they give no information on the exact structures of the
MBs isolated (38). At least three different structures for MB J
(the major MB from M. paratuberculosis) have appeared, the
final one without comment in the context of other work (4, 18,
49). In addition, recent work on the carboxy-MBs or the chlo-
roform-extractable exochelins has added to the complexity of
the situation (18, 36, 37, 81). These compounds are clearly
MBs with a modified acyl group (R5) derived from a dicar-
boxylic acid. This may be present as the free acid, the methyl
ester, or a mixture of the two. Once again, a number of ana-
logues are observed, with 20 different compounds identified
from M. avium that differ only at R5 (81).
Nomenclature of extracellular MBs. The small structural
difference between the prototypical MBs and the extracellular
compounds, i.e., the presence of an additional carboxyl or ester
functionality on R5, leads to a profound increase in water
solubility. This prompted the two groups of workers involved
to each suggest a new name for this class of compounds, i.e.,
the carboxy-MBs (37) or the exochelins (18). Unfortunately,
both are problematic. The name exochelin has already been
applied to structurally unrelated, extracellular, peptidic sid-
erophores from M. smegmatis (71) and M. neoaurum (70) and
belies the structural similarity of these exochelins and the MBs.
The name carboxy-MB, while addressing the latter concern, is
inappropriate, as both the methyl esters and the free acids of
these compounds have been reported (81). It seems best sim-
ply to refer to this class of compounds as water-soluble MBs, a
term that is indicative of both their structure and their distin-
guishing physical characteristic. (The actual situation is even
more complex. Ratledge and coworkers discovered water-sol-
uble, mycobacterial siderophores and collectively termed them
exochelins [42]. It was known that there were at least two types
based on solubilities [43], and the first to be structurally char-
acterized were peptidic compounds unrelated to MBs and
named exochelins [70, 71]. Subsequently, the water-soluble
MBs were identified [18, 37].) The more insightful term exo-
MB, which evokes both the putative functional difference of
these compounds from and the structural similarity of these
compounds to cell-associated MBs, has also been used to de-
scribe these extracellular MB analogs (84).
As might be expected for such a complex array of structures,
systematic chemical nomenclature is too unwieldy and trivial
names are generally employed. The best system still appears to
be that suggested by Snow in his excellent review in 1970 (73).
Families of MBs are identified by their core structures, each of
which is indicated by a letter referring to a previously identified
MB. The letter historically indicated the species from which
the compound was isolated, e.g., MB P from M. phlei.
A second structural class of siderophores: exochelins. The
existence of a second family of mycobacterial siderophores has
been recognized for some time (42), but only recently have
some of its members been characterized (70, 71). Two struc-
tures are known, both highly modified peptides with iron co-
ordination sites provided by hydroxamic acids derived from or-
nithine (71), and in one case, a novel b-hydroxyhistidine (70).
Exochelin MS (Fig. 1B), the major exochelin from M. smeg-
matis, reportedly representing 25 to 35% of the total of these
compounds in this organism, was shown to be a formylated
pentapeptide derived from three molecules of d-N-hydroxyor-
nithine, a b-alanine, and a threonine. Hydroxamic acids de-
rived from the three ornithine moieties provide the iron coor-
dination sites. Exochelin MN, one of the exochelins from M.
neoaurum, is a hexapeptide consisting of two d-N-hydroxyorni-
thine residues and a b-hydroxyhistidine, which provide the iron
coordination sites; two b-alanines; and an ornithine. The dif-
ferences between exochelin MS and exochelin MN implies that
there is a greater variation in structure and iron coordination
strategy in this class of siderophore than is seen in the MBs.
Thus far, such peptidic siderophores have only been reported
from rapidly growing saprophytic mycobacterial species.
BIOSYNTHESIS OF MYCOBACTERIAL SIDEROPHORES
The basic building blocks. Soon after the first structure of an
MB was reported, the identities of the basic biosynthetic build-
ing blocks were elucidated (Fig. 2). It was shown that L-lysine
was the precursor of both e -N-hydroxylysines through radiola-
beling studies (1, 78). The b-hydroxy acid moiety was shown to
be derived from the condensation of two propionate molecules
in the case of the 2-methyl-3-hydroxypentanoic acid of MB P
(78). Results obtained with [1-14C]acetate were consistent with
the b-hydroxybutyrate and the acyl moiety at R5 of MB S being
derived from acetate (78). The aromatic moiety of MB S from
M. smegmatis has been shown to arise from salicylate formed
via the shikimic acid pathway (27, 62, 63). The aromatic moiety
of MB P, with its extra methyl group, is believed to arise from
6-methylsalicylate instead of salicylate. Once again, this acid is
a known extracellular metabolite in mycobacteria that forms
MBs bearing the methylated aromatic moiety (73). However,
the biosynthetic origins of these two aromatic acids are very
different. In contrast to salicylate, 6-methylsalicylate is not a
shikimate metabolite but rather a polyketide formed from the
condensation of four acetate units (28). This provides an in-
teresting example of two very different biosynthetic pathways
being utilized to provide the required structural unit, a hy-
droxyaromatic acid. Even more surprising is the co-occurrence
of MBs in M. fortuitum (75) that have both a salicylate- and a
6-methylsalicylate-derived aromatic moiety. This implies that
both pathways must apparently be employed by this organism
(73). No studies have been carried out on the origins of the
oxazoline, but serine and threonine are presumed to be the
precursors of the unsubstituted and methyl-bearing rings, re-
spectively (73).
The enzymes which assemble MBs belong to the family of
nonribosomal peptide synthases. Studies of MB biosynthesis
have languished for the last 20 years, only to be reinvigorated
by the recent sequencing of the M. tuberculosis genome. A gene
cluster designated the mbt genes was recognized by Cole et al.
(8) and by Quadri et al. (56) as having the potential to encode
the appropriate enzymes for MB formation (Fig. 4A). Several
of the encoded proteins are highly homologous to nonriboso-
mal peptide synthases (NRPSs), which have been implicated in
the biosynthesis of other siderophores, as well as a variety of
peptide-derived secondary metabolites (44). These NRPSs are
large modular enzymes that activate amino acids as their acyl
adenylates through an activating domain and covalently link
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FIG. 4. Proposed biosynthetic scheme for MB T. (A) Region of the genome of M. tuberculosis H37Rv containing the putative MB biosynthetic enzymes. Numbering
refers to chromosomal positions reported by Cole et al. (8). (B) Proposed biosynthetic cascade catalyzed by the Mbt locus. See the text for details of individual enzymatic
predictions. There are significant areas of uncertainty in this model, as suggested by the following questions. (i) Does the ketoacyl synthase domain of MbtC act upon
the MbtD-bound acyl carrier protein domains as shown? (ii) Does the second peptidyl/acyl carrier protein domain of MbtE function to attach the b-hydroxybutyrate
as shown, or does it transfer the acyl group to the first lysine (the R5) position in Fig. 2? (iii) Do MbtE and MbtF act in the order in which they appear in the genomic
locus, or are they reversed? (iv) Is MbtG involved in N-hydroxylation as shown? (v) What is the nature of the acyltransferase, and how is the specificity determined?
When does this act and upon what substrate? Since this determines the ratio of water-soluble to cell-associated siderophore, this is a critical question. (vi) What is the
role played by MbtH and MbtJ?
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them to the enzyme via a phosphopantetheinyl thioester at-
tached to a peptide carrier protein domain. Two such activated
amino acids are then condensed to form a peptide bond in a
reaction catalyzed by a condensation domain. The activation
domains specify the amino acids incorporated, and their order
encodes the sequence of the final peptide. Numerous other
domains or activities are also encountered in these proteins,
i.e., epimerization domains that convert L amino acids to D
amino acids, cyclization domains that form either macrocyclic
esters or amides or smaller rings such as oxazolines and thia-
zolines, and thioesterase domains that cleave the final peptide
product from the enzyme.
A unified scheme for the production of MBs. The proposed
biosynthetic scheme based upon the known precursor incorpo-
ration results and the sequence homologies of the deduced
mbt-encoded proteins is as follows (Fig. 4B). Salicylate is ac-
tivated as its acyl adenylate by MbtA (Rv2384) and is then
covalently attached to a phosphopantetheine prosthetic group
of MbtB (Rv2383c). This activation-attachment appears to be
a common motif in the biosynthesis of siderophores which
contain a phenolate moiety. Proteins homologous to MbtA
have been observed in the biosynthetic pathways of enterobac-
tin (67) from Escherichia coli and yersiniabactin from Yersinia
pestis (16). MtbB is an NRPS that is believed to activate serine,
condense it with the salicylate moiety, and cyclize this product
to a hydroxyphenyloxazoline. Once again, MtbB has homo-
logues with analogous functions in both the pyochelin (from
Pseudomonas aeruginosa) (66) and yersiniabactin (16) path-
ways. There are two other NRPSs, encoded by mbtE (Rv2380c)
and mbtF (Rv2379c), that have the appropriate activation,
condensation, and peptide carrier domains for donation of the
two lysine-derived moieties of MB. MbtF has a terminal do-
main that was assigned a role as either an epimerization do-
main or as a thioesterase responsible for releasing the MB
from the enzyme by lactamization of the terminal hydroxy-
lysine residue. The latter function appears much more likely, as
all amino acid-derived centers with known absolute configura-
tions in the MBs arise from the naturally occurring L series
(25, 73, 75, 76). It should be noted, however, that the absolute
stereochemistries of the oxazoline and the acylated lysine (i.e.,
b and c in Fig. 3) have not been determined unambiguously for
MB T, the MB from M. tuberculosis. Also in the gene cluster
are mbtC (Rv2382c) and mbtD (Rv2381c), which encode pro-
teins that are homologous to polyketide synthases. The en-
coded proteins appear to contain the appropriate modules to
produce the required b-hydroxybutyrate. Additionally, mbtG
(Rv2378c) encodes a protein that is homologous to known
ornithine and lysine oxygenases, an activity required for the
production of the e -N-hydroxylysines. Thus, these seven genes,
mbtA to mbtG, appear to encode sufficient activities for the
biosynthesis of the core of the MBs (Fig. 4). There are two
other proposed gene products, MbtH (Rv2377c) and MbtJ
(Rv2385), to which no clear biochemical role has been as-
signed.
The genes involved in the formation of salicylate are not
clearly defined. Cole et al. (8) suggested that a distinct operon
with two genes (entC and entD [Rv3215 and Rv3214, respec-
tively]) homologous to those implicated in salicylate formation
in P. aeruginosa (69) is responsible for its formation. Walsh et
al. (56) concluded that the product of another gene, mbtI
(Rv2386c), located at the 59 end of the mbt gene cluster and
homologous to salicylate- and anthranilate-forming enzymes
was most likely to be responsible for salicylate formation. This
gene was originally called trpE2 and assigned the encoding of
an anthranilate synthase (8). Given the similarity between the
different biochemical functions postulated for these various
enzymes (anthranilate is the amino analog of salicylate), cer-
tain assignment will await the expression and characterization
of these proteins. It is interesting, however, that the DNA
sequence upstream of the mbtI gene contains a very convincing
match for an IdeR binding consensus sequence, which suggests
repression of the expression of this gene under high-iron con-
ditions, consistent with a predicted role in salicylate synthesis
(13). It should also be noted that a gene (acpS [Rv2523c])
which encodes a phosphopantetheinyl transferase, necessary
for the formation of the holoenzyme of the NRPSs, has been
identified in the M. tuberculosis genome (56).
What proof exists for the function of the above enzymes
(MbtA to MbtG), postulated on the basis of homology alone?
The protein encoded by mbtA has been expressed and shown
to form the acyl adenylate of salicylate (56). This, in turn,
acylates a fragment of MbtB which was predicted to encode the
necessary phosphopantetheinyl carrier domain. This only oc-
curred after treatment of the MbtB protein fragment with the
appropriate phosphopantetheinyl transferase (56). We have
constructed an mbtB mutant strain of M. tuberculosis through
homologous recombination with a DNA fragment in which a
portion of the mbtB gene was replaced with a hygromycin
resistance marker (10). The resulting DmbtB::hyg strain was
shown to be incapable of siderophore production, thus conclu-
sively linking this gene cluster with MB biosynthesis. The ab-
sence of siderophore production in this mutant furthermore
demonstrates that all of the MBs, including the water-soluble
ones, arise through a common biogenic pathway. This latter
work (10) also was the first to demonstrate the long-suspected
importance of siderophore production to virulence in M. tu-
berculosis, as the mbtB mutant strain was avirulent in macro-
phage infections. Thus, the importance of this operon in MB
biosynthesis has been established. The roles of MbtA and
MbtB (in part) are as predicted, but the completion of much of
the MB biosynthetic story awaits the functional characteriza-
tion of the remaining enzymes.
The biosynthesis of exochelins. Recently, some results con-
cerning the biosynthesis of the other mycobacterial sidero-
phore, the exochelins, have been reported (14, 83, 84).
Complementation studies carried out with M. smegmatis mu-
tants defective in exochelin production have identified a cluster
of three genes believed to be involved in the biosynthesis of
exochelin MS (the exochelin from M. smegmatis). Two of these
genes encode large NRPSs (83, 84), while the third encodes a
protein with homology to phosphoribosylglycineamide formyl-
transferases (14). This latter enzyme was believed to be re-
sponsible for the production of the formylornithine moiety of
exochelin MS, while the NRPSs catalyzed the assembly of the
peptide backbone. However, the identification of a total of six
amino acid activation domains for the production of this pen-
tapeptide indicates that, as with the MBs, much remains to be
understood about exochelin biosynthesis. Part of the explana-
tion for this discrepancy may lie in the fact that exochelin MS
is only one of the family of exochelins produced by M. smeg-
matis.
THE REGULATION OF IRON METABOLISM
Iron-responsive alterations in protein synthesis. Combina-
tion of sophisticated mass spectrometry techniques with the
genome sequence to analyze protein patterns on two-dimen-
sional gels has been a useful tool in the identification of pro-
teins that are upregulated or downregulated in response to
iron concentration (82). Fifteen proteins from M. tuberculosis
were upregulated and 12 proteins were downregulated under
low-iron conditions. In another study of protein profiles of M.
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tuberculosis grown in low and high concentrations of iron,
several iron-regulated proteins were isolated by sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis and subjected to
N-terminal sequencing (6). The gene encoding Irp10, a 10-kDa
protein prominent in iron-deficient cell extracts but virtually
absent from extracts of iron-replete cultures, was designated
irpA (Rv3269). This gene is similar to those that encode heat
shock proteins or chaperonins and lies immediately upstream
of a gene that encodes a putative cation-transporting ATPase
named CtpC (Rv3270). This protein is a member of the P-type
cation-transporting ATPase family. Both irpA and ctpC appear
to be induced by low iron, although no consensus binding sites
for known iron-dependent regulators were identified upstream
of either gene. If further studies reveal that Irp10 and CtpC do,
in fact, transport iron, it will be the first example of iron
transport by a P-type ATPase, rather than an ABC transporter
ATPase.
The N-terminal sequences of two other iron-regulated pro-
teins that were upregulated under low-iron conditions were
also reported (6). By searching the M. tuberculosis genome
database, it is now possible to identify these proteins. The
N-terminal sequence of the upregulated Irp13 protein corre-
sponds to Acr (Rv2031c), the same protein previously shown
by these authors to be downregulated by iron starvation (82).
Irp28 contains the sequence found in HupB (Rv2986c), an
HU-histone fusion. Interestingly, the same N-terminal se-
quence was found for both Irp28 and Irp29. While Irp28 is
upregulated by iron starvation, Irp29 is downregulated by iron
starvation, suggesting that the same histone-like protein is
modified differently under the two conditions.
Phenotypic responses to iron deprivation. The effect of iron
starvation on stress response-related protein synthesis in M.
smegmatis was examined (39). Killing by hydrogen peroxide
was increased in cultures grown in 0.2 mM or a lower iron
concentration. The simplest interpretation is that during iron
starvation, iron-containing enzymes, such as catalase, which
are required for protection from hydrogen peroxide are not
produced in their active, iron-containing form. However, the
situation may be more complicated. Patterns of stress-induced
proteins were examined by placing M. smegmatis under heat,
ethanol, or hydrogen peroxide stress while labeling the induced
proteins with 35S. When the labeling experiments were per-
formed with iron-sufficient cells, all three stress conditions
induced expression of GroEL1 (Rv3417c) and DnaK (Rv0350).
Surprisingly, when the labeling experiments were done with
iron-starved cells, GroEL and DnaK were not induced by hy-
drogen peroxide but were induced by heat shock or ethanol,
suggesting that the regulatory networks involved in iron me-
tabolism and stress responses are interrelated. The response of
iron-starved M. tuberculosis to hydrogen peroxide stress may
differ from that described for M. smegmatis, since M. smegmatis
displays a broader phenotypic response to oxidative stress than
does M. tuberculosis (72).
Control of gene expression by iron in mycobacteria. The
best-studied iron-responsive transcriptional regulator is the
ferric uptake regulator Fur (9). Encoded by the fur gene, this
protein binds its corepressor, ferric iron, and then binds to
operator sequences known as Fur boxes, thereby repressing
transcription. Under iron starvation, Fur no longer binds to the
Fur box and the corresponding genes become derepressed. M.
tuberculosis contains as many as four such iron-dependent reg-
ulators. IdeR (Rv2711) is the only protein for which experi-
mental evidence of a role in iron binding and DNA binding
exists (68). It contains extensive similarity to the DtxR family.
This family, named after the diphtheria toxin repressor, is only
distantly related to the gram-negative iron-dependent regula-
tor Fur and binds a different DNA operator sequence. Inter-
estingly, M. tuberculosis contains two genes, furA and furB, that
encode proteins more similar to E. coli Fur than to IdeR/DtxR.
FurA (Rv1909c) clusters more tightly with Fur proteins found
in other mycobacteria and FurS from Streptomyces reticuli. In
each case, immediately downstream of the fur homolog is a
gene encoding a catalase peroxidase. In the mycobacteria, this
gene is katG; in S. reticuli, it is called cpeB. In S. reticuli, FurS
has been shown to negatively regulate the expression of cpeB in
the presence of iron (85). The sequence similarity of both the
regulator and catalase-peroxidase, as well as the conserved
gene arrangement, suggests functional conservation between
S. reticuli and M. tuberculosis. Even more similar to E. coli Fur
is FurB (Rv2359), for which no other mycobacterial homologs
have been described. Finally, there is SirR (Rv2788), putatively
described as an iron-dependent regulator based on similar-
ity to SirR from Staphylococcus epidermidis (23), TroR from
Treponema pallidum (21), and the IdeR/DtxR family.
The iron-responsive regulatory protein encoded by ideR,
which is homologous to the dtxR gene from Corynebacterium
diphtheriae, is biochemically the best characterized. The myco-
bacterial protein has been analyzed both in vitro and in vivo for
function. The recombinant protein overproduced in E. coli was
shown by band shift analysis to bind the C. diphtheriae tox
promoter-operator sequence in a divalent metal-dependent
manner (68). The role of IdeR in the repression of siderophore
production was shown with the construction of an ideR mutant
of M. smegmatis (13). This mutant produces siderophore when
grown in high- or low-iron media, demonstrating the require-
ment for IdeR to repress siderophore production under high-
iron conditions. Interestingly, but perhaps not surprisingly in
light of the presence of furA, furB, and sirR in M. tuberculosis,
the mutant was still capable of upregulating siderophore pro-
duction under low-iron conditions, suggesting the presence of
a second iron-sensing regulator in M. smegmatis. Another phe-
notype associated with the ideR mutant was increased sensitiv-
ity to hydrogen peroxide. Native gel activity assays demon-
strated a reduction in the activities of the catalase-peroxidase
KatG and the superoxide dismutase activity of Mn superoxide
dismutase. However, the activity of another catalase, KatE,
was unaffected by the ideR mutation. These results again dem-
onstrate the link between the responses to iron starvation and
oxidative stress in M. smegmatis.
CONCLUSIONS
Iron is an essential nutrient whose concentration is critical in
determining the outcome of infection with pathogenic myco-
bacteria. These organisms have evolved a complex web of
biosynthetic and metabolic pathways by which to obtain it,
store it, and regulate its use. Unraveling of the intricacies of
this system may reveal an Achilles heel that can be used to
guide and inform the development of new antibiotics. As a
precedent for such antibiotics, p-aminosalicylic acid is a clini-
cally useful second-line antitubercular agent, the target of
which may lie in the enzymes which biosynthesize MBs (80).
MB structural analogs have inhibitory potential as well, attract-
ing the interest of synthetic chemists. M. tuberculosis, which
biosynthesizes and utilizes MB T, is inhibited by synthetic MB
S, which only appears to differ from MB T in the absolute
configuration of one to three of its stereogenic centers (26, 73).
Further progress toward new therapies based upon a rational
understanding of iron acquisition and metabolism by mycobac-
teria requires an even greater understanding of the complexi-
ties of the structure, biosynthesis, and functions of sidero-
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phores; their uptake into bacterial cells; and the long-term
storage and retrieval of iron.
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